Protagonist Therapeutics, Inc. (PTGX)
PTGX Stock Price Chart
Key Info
| Market Cap | 814.87M |
| Revenue (ttm) | 25.70M |
| Net Income (ttm) | -64.77M |
| Shares Out | 37.39M |
| EPS (ttm) | -2.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 3 |
| Last Price | $21.30 |
| Previous Close | $21.99 |
| Change ($) | -0.69 |
| Change (%) | -3.14% |
| Day's Open | 21.68 |
| Day's Range | 21.04 - 22.86 |
| Day's Volume | 235,884 |
| 52-Week Range | 5.40 - 24.16 |
PTGX Stock News
NEWARK, Calif., Sept. 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate...
NEWARK, Calif., Sept. 15, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.
NEWARK, Calif., Sept. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.
NEWARK, Calif., Sept. 2, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.
NEWARK, Calif., Aug. 13, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.51% and 63.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for t...
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharmaceutical stocks dipped by a single-digit percentage in the first six months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.
Why Protagonist Should Be On Your Radar After Latest Trial Update
The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromato...
NEWARK, Calif., June 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation...
NEWARK, Calif., June 16, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate ...
Protagonist Therapeutics: Robust Polycythemia Vera Data Is Just The Beginning
NEWARK, Calif., June 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the company will present data from its Phase 2 trial of PTG-300 for the treatment...
NEWARK, Calif., May 28, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at tw...
Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q1 2020 Results - Earnings Call Transcript
Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q1 2020 Results - Earnings Call Transcript
Here's what's behind their impressive market performances.
Shares of micro-cap biopharmaceutical company Protagonist Therapeutics (PTGX) soared on Friday, and were up over 90% at one point in afternoon trading.
Why is Protagonist Therapeutics (PTGX) Soaring 90% Today?
zacks.com zacks.com/ultimate
The company is set to start a pivotal study for one of its lead pipeline candidates.
Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2019 Results - Earnings Call Transcript
Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2019 Results - Earnings Call Transcript
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 1.56% and -48.21%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead f...
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
Protagonist's Upcoming Catalyst Has The Potential To Carve Out A Solid Path With Lead Drug
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 18.67% and -27.98%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead...
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -337.04% and -176.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead f...
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 10.77% and -37.60%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for...
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About PTGX
Protagonist Therapeutics, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat patients with moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta... [Read more...]
| Industry Biotechnology | IPO Date Aug 11, 2016 |
| Employees 76 | |
| Stock Exchange NASDAQ | Ticker Symbol PTGX |
Financial Performance
In 2019, PTGX's revenue was $231,000, a decrease of -99.25% compared to the previous year's $30.93 million. Losses were -$77.19 million, 98.3% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for PTGX is 31.75, which is an increase of 49.06% from the latest price.